MINI FUTURE SHORT - BIOMERIEUX Stock

Certificat

DE000MD7RQ40

Real-time Bid/Ask 05:32:02 2024-05-29 am EDT
4.04 EUR / 4.06 EUR +2.53% Intraday chart for MINI FUTURE SHORT - BIOMERIEUX
Current month+16.18%
1 month+22.67%
Date Price Change
24-05-29 4.04 +2.28%
24-05-28 3.95 +2.07%
24-05-27 3.87 +1.31%
24-05-24 3.82 -2.05%
24-05-23 3.9 -0.76%

Delayed Quote Börse Stuttgart

Last update May 29, 2024 at 03:52 am EDT

More quotes

Static data

Product typeCertificat Turbo Stop Loss
Buy / SellPUT
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MD7RQ4
ISINDE000MD7RQ40
Date issued 2022-09-01
Strike 134.1
Maturity Unlimited
Parity 10 : 1
Emission price 4.07
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 5.8
Lowest since issue 2.76
Spread 0.02
Spread %0.50%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
94.15 EUR
Average target price
114.2 EUR
Spread / Average Target
+21.26%
Consensus